Publications by authors named "Bahar Yilmazel"

Claim this Profile
A
Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples.
Wenshu Li, Jeffrey A Leibowitz, Shuoguo Wang, Louisa Walker, Chang Xu, Bahar Yilmazel

PLoS One· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy.
Derek W Brown, Daokun Sun, Alexander D Fine, Shai He, Michael McDevitt, Bahar Yilmazel

J Liq Biopsy· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Ian M Silverman, Meijuan Li, Karthikeyan Murugesan, Melanie A Krook, Milind M Javle, Bahar Yilmazel

J Mol Diagn· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET rearrangements are actionable alterations in breast cancer.
Bhavna S Paratala, Jon H Chung, Casey B Williams, Bahar Yilmazel, Whitney Petrosky

Nat Commun· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
Fiona C Brown, Paolo Cifani, Esther Drill, Jie He, Eric Still, Bahar Yilmazel

Br J Haematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets.
Arunachalam Vinayagam, Travis E Gibson, Ho-Joon Lee, Bahar Yilmazel, Charles Roesel

Proc Natl Acad Sci U S A· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi.
Benjamin E Housden, Alexander J Valvezan, Colleen Kelley, Richelle Sopko, Yanhui Hu, Bahar Yilmazel

Sci Signal· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification.
Umut Disel, Alexis Germain, Bahar Yilmazel, Huseyin Abali, Filiz Aka Bolat

Oncoscience· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis.
Bahar Yilmazel, Yanhui Hu, Frederic Sigoillot, Jennifer A Smith, Caroline E Shamu

BMC Bioinformatics· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating protein-protein interaction networks with phenotypes reveals signs of interactions.
Arunachalam Vinayagam, Jonathan Zirin, Charles Roesel, Yanhui Hu, Bahar Yilmazel

Nat Methods· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis